Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm PharmaceuticalsCAI:MIPH -0.62%50 EV-to-EBITDA is 7.68 as of Aug. 14, 2026, which is 107% above its 10-year median of 3.71. GuruFocus rates CAI:MIPH with a GF Score™ of 50/100 and a GF Value™ of E£368.05 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 735 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 72.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Minapharm Pharmaceuticals's enterprise value is E£10,313 Mil.
Minapharm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was E£1,343 Mil. Therefore, Minapharm Pharmaceuticals's EV-to-EBITDA for today is 7.68.
The historical rank and industry rank for Minapharm Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
CAI:MIPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.12 Med: 3.71 Max: 11.17
Current: 7.68
During the past 5 years, the highest EV-to-EBITDA of Minapharm Pharmaceuticals was 11.17. The lowest was 2.12. And the median was 3.71.
CAI:MIPH's EV-to-EBITDA is ranked better than 72.93% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs CAI:MIPH: 7.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Minapharm Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Minapharm Pharmaceuticals's share price for today is E£773.73.
Minapharm Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£0.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's EV-to-EBITDA falls into.
Minapharm Pharmaceuticals's current Enterprise Value is E£10,313 Mil.
Minapharm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£1,343 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a EV-to-EBITDA of 7.68 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Minapharm Pharmaceuticals. This is 107% above median its historical median of 3.71. Over the past decade, Minapharm Pharmaceuticals' EV-to-EBITDA has ranged from 2.12 to 11.17. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #199 out of 735 companies in the Drug Manufacturers industry, placing it in the top 27.1%.
Is Minapharm Pharmaceuticals' EV-to-EBITDA too high?
Minapharm Pharmaceuticals' current EV-to-EBITDA of 7.68 is 107% above median its 10-year median of 3.71. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 11.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Minapharm Pharmaceuticals' value of 7.68 is 42.3% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #199 out of 735 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #199 out of 735 companies for EV-to-EBITDA. This puts Minapharm Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 13.30. Minapharm Pharmaceuticals' value of 7.68 is 42.3% below this benchmark. Historically, Minapharm Pharmaceuticals' own EV-to-EBITDA has ranged from 2.12 to 11.17 over the past decade. While the company's 10-year median is 3.71 vs. the industry median of 13.30, Minapharm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current EV-to-EBITDA of 7.68 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Minapharm Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current EV-to-EBITDA is 7.68, which is 107% above median its own 10-year median of 3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£368.05, compared to a current price of E£773.73 — trading 110.2% above its estimated fair value. The current EV-to-EBITDA is 7.68, which is 107% above median its 10-year median of 3.71 and 42.3% below the Drug Manufacturers industry median of 13.30. Minapharm Pharmaceuticals' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current EV-to-EBITDA is 7.68 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£773.73 is trading 110.2% above its estimated GF Value™ of E£368.05.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
EV-to-EBITDA: 7.68 (107% above median its 10-year median of 3.71)
GF Value™: E£368.05 vs. price of E£773.73 (110.2% above fair value)
Industry Position: 42.3% below the Drug Manufacturers median (#199 of 735)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
50GF Score
Get the complete analysis for CAI:MIPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
